Filing Flows › Silence Therapeutics (SLN) › Recalls, complaints & regulation

Silence Therapeutics (SLN): clinical trials

Silence Therapeutics (SLN) beyond its filings: 1 active clinical trial.

Silence Therapeutics' latest quarter

Silence Therapeutics, Q1 2026: revenue $422K (+197% year over year), net loss $15.0M, operating cash flow −$15.6M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Silence Therapeutics have?

1 active study on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.